BGC
GILD icon

Blue Granite Capital’s Gilead Sciences GILD Stock Holding History

Blue Granite Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$615K Sell
8,550
-6,456
-43% -$490K 0.45% 33
2017
Q3 		$1.21M Sell
15,006
-33,772
-69% -$2.58M 0.84% 53
2017
Q2 		$3.46M Buy
48,778
+400
+0.8% +$26.6K 2.24% 10
2017
Q1 		$3.29M Buy
48,378
+6,750
+16% +$475K 2.15% 13
2016
Q4 		$2.98M Buy
+41,628
New +$3.09M 2.12% 15

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Blue Granite Capital's GILD Position: Q4 2017 in Review

Blue Granite Capital reduced its Gilead Sciences (GILD) stake by 43% in Q4 2017, selling an estimated $490K and leaving 8,550 shares worth $615K. The position accounts for 0.45% of the portfolio, ranked #33.

Blue Granite Capital first reported a position in GILD in Q4 2016 and has held it in 5 quarters since. The position peaked at $3.46M in Q2 2017. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

  • Blue Granite Capital held 8,550 shares of Gilead Sciences worth $615K as of Q4 2017.
  • Blue Granite Capital sold 6,456 Gilead Sciences shares in Q4 2017, an estimated $490K.
  • Gilead Sciences made up 0.45% of Blue Granite Capital's portfolio in Q4 2017, its #33 holding.
  • Blue Granite Capital first reported a position in Gilead Sciences in Q4 2016 and has held it in 5 quarters since.
  • Blue Granite Capital's Gilead Sciences position peaked at $3.46M in Q2 2017.
  • 1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Blue Granite Capital's 13F filing for Q4 2017, filed 14 Feb 2018.